{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:23:36Z","timestamp":1790497416529,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T00:00:00Z","timestamp":1367884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10549-013-2553-7","type":"journal-article","created":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T02:03:23Z","timestamp":1367805803000},"page":"507-513","source":"Crossref","is-referenced-by-count":32,"title":["Beta blockers and angiotensin-converting enzyme inhibitors\u2019 purported benefit on breast cancer survival may be explained by aspirin use"],"prefix":"10.1007","volume":"139","author":[{"given":"Michelle D.","family":"Holmes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Hankinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Feskanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,7]]},"reference":[{"issue":"2","key":"2553_CR1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/bcr3336","volume":"14","author":"MD Holmes","year":"2012","unstructured":"Holmes MD, Chen WY (2012) Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res 14(2):216. doi: 10.1186\/bcr3336","journal-title":"Breast Cancer Res"},{"issue":"3","key":"2553_CR2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc1820","volume":"6","author":"MH Antoni","year":"2006","unstructured":"Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6(3):240\u2013248. doi: 10.1038\/nrc1820","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2553_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2011.01.009","volume":"130","author":"C Vaklavas","year":"2011","unstructured":"Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011) Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 130(2):177\u2013190. doi: 10.1016\/j.pharmthera.2011.01.009","journal-title":"Pharmacol Ther"},{"issue":"18","key":"2553_CR4","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","volume":"70","author":"EK Sloan","year":"2010","unstructured":"Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042\u20137052. doi: 10.1158\/0008-5472.CAN-10-0522","journal-title":"Cancer Res"},{"issue":"3","key":"2553_CR5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01612908","volume":"116","author":"B Vandewalle","year":"1990","unstructured":"Vandewalle B, Revillion F, Lefebvre J (1990) Functional beta-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116(3):303\u2013306","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"2553_CR6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.18632\/oncotarget.197","volume":"1","author":"DG Powe","year":"2010","unstructured":"Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628\u2013638","journal-title":"Oncotarget"},{"issue":"19","key":"2553_CR7","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","volume":"29","author":"A Melhem-Bertrandt","year":"2011","unstructured":"Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645\u20132652. doi: 10.1200\/JCO.2010.33.4441","journal-title":"J Clin Oncol"},{"key":"2553_CR8","doi-asserted-by":"crossref","unstructured":"Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. doi: 10.1007\/s10549-011-1505-3","DOI":"10.1007\/s10549-011-1505-3"},{"issue":"19","key":"2553_CR9","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","volume":"29","author":"TI Barron","year":"2011","unstructured":"Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29(19):2635\u20132644. doi: 10.1200\/JCO.2010.33.5422","journal-title":"J Clin Oncol"},{"issue":"3","key":"2553_CR10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ygyno.2008.02.019","volume":"109","author":"D Herr","year":"2008","unstructured":"Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, Wulff C (2008) Potential role of renin\u2013angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 109(3):418\u2013425. doi: 10.1016\/j.ygyno.2008.02.019","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2553_CR11","first-page":"573","volume":"63","author":"WP Koh","year":"2003","unstructured":"Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC (2003) Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 63(3):573\u2013578","journal-title":"Cancer Res"},{"issue":"2","key":"2553_CR12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/carcin\/bgh309","volume":"26","author":"WP Koh","year":"2005","unstructured":"Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC (2005) Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26(2):459\u2013464. doi: 10.1093\/carcin\/bgh309","journal-title":"Carcinogenesis"},{"issue":"2","key":"2553_CR13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jcp.10313","volume":"196","author":"S Greco","year":"2003","unstructured":"Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, Manca C, Marsigliante S (2003) Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196(2):370\u2013377. doi: 10.1002\/jcp.10313","journal-title":"J Cell Physiol"},{"issue":"1","key":"2553_CR14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcp.22209","volume":"225","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S (2010) Angiotensin II\/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase\/Akt pathway. J Cell Physiol 225(1):168\u2013173. doi: 10.1002\/jcp.22209","journal-title":"J Cell Physiol"},{"issue":"9","key":"2553_CR15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/07357907.2011.616252","volume":"29","author":"YK Chae","year":"2011","unstructured":"Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and\/or statins. Cancer Investig 29(9):585\u2013593. doi: 10.3109\/07357907.2011.616252","journal-title":"Cancer Investig"},{"key":"2553_CR16","doi-asserted-by":"crossref","unstructured":"Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol. doi: 10.1200\/JCO.2009.22.7918","DOI":"10.1200\/JCO.2009.22.7918"},{"issue":"2","key":"2553_CR17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10549-011-1651-7","volume":"130","author":"MD Holmes","year":"2011","unstructured":"Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, Tamimi RM (2011) COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 130(2):657\u2013662. doi: 10.1007\/s10549-011-1651-7","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2553_CR18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10552-007-9003-y","volume":"18","author":"ML Kwan","year":"2007","unstructured":"Kwan ML, Habel LA, Slattery ML, Caan B (2007) NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18(6):613\u2013620. doi: 10.1007\/s10552-007-9003-y","journal-title":"Cancer Causes Control"},{"issue":"2","key":"2553_CR19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-006-9277-x","volume":"101","author":"CK Blair","year":"2007","unstructured":"Blair CK, Sweeney C, Anderson KE, Folsom AR (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101(2):191\u2013197. doi: 10.1007\/s10549-006-9277-x","journal-title":"Breast Cancer Res Treat"},{"key":"2553_CR20","doi-asserted-by":"crossref","unstructured":"Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. doi: 10.1016\/S1470-2045(12)70112-2","DOI":"10.1016\/S1470-2045(12)70112-2"},{"issue":"9826","key":"2553_CR21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591\u20131601. doi: 10.1016\/S0140-6736(12)60209-8","journal-title":"Lancet"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2553-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2553-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2553-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:47:16Z","timestamp":1559234836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2553-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,7]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["2553"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2553-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,7]]}}}